Jacob E. Berchuck, MD, discussed research behind using a blood-based liquid biopsy in prostate cancer and findings presented at the 2024 ESMO Congress. Jacob E. Berchuck, MD A novel epigenetic liquid biopsy platform for determining tumor prostate-specific membrane antigen (PSMA) expression in ...
complicated process, and there are still not many biomarkers based on extracellular vesicles in clinical use. However, the knowledge acquired during the last decade constitutes a solid basis for the future development of liquid biopsy tests for prostate cancer. These are urgently needed to bring pros...
A novel liquid biopsy aid for identifying clinically significant prostate cancer in at-risk men: Combining artificial intelligence with flow cytometry-based immunophenotypinge17508 Background: Current screening methods for prostate cancer (PCa) ... G Dominguez,AJ Campisi,J Roop,... - 《Journal of ...
called a "liquid biopsy," could accurately distinguishprostate cancerfrom normal controls without prior knowledge of the genetic "signature" of the tumors, and with over three times the sensitivity of current prostate-specific antigen (PSA) screening. ...
Liquid biopsy of tumor-derived extracellular vesicles (EVs) has great potential as a biomarker source for prostate cancer (CaP) early diagnosis and predicting the stages of cancer. The contents of EVs play an important role in intercellular communication and have specific expression in blood and uri...
The new liquid biopsy test from Predicine is also more informative than previous tests as it analyzes two types of genetic material—DNA and RNA—to give a more in-depth and accurate insight into AR abnormalities within thecancer. More information:Heidi Fettke et al. Combined Cell-free DNA ...
Liquid biopsy assays are important to prognosticate outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients treated with androgen receptor (AR) inhibitors. Here this group reports detecting circulating tumor DNA in limiting plasma cell-free DNA of mCRPC patients as prognostic marker ...
Metastatic prostate cancer is a highly heterogeneous and dynamic disease and practicable tools for patient stratification and resistance monitoring are urgently needed. Liquid biopsy analysis of circulating tumor cells (CTCs) and circulating tumor DNA are promising, however, comprehensive testing is essential...
in Prostate Cancer Liquid Biopsy Characterizing Circulating Tumor Cells Can Aid Treatment Selection in Prostate CancerLiquid Biopsy Characterizing Circulating Tumor Cells Can Aid Treatment Selection in Prostate CancerPhoebe Starr
The study used a liquid biopsytestdeveloped by molecular diagnostics company Epic Sciences that examines circulating tumour cells (CTCs) in blood samples from patients with advancedprostatecancerwho are deciding whether to switch from hormone-targeting therapy to chemotherapy. CTCs are cancer cells that ...